Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

CLLS Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Cellectis S.A.NASDAQ: CLLS

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $28.35M rose 24.2% year over year, ahead of the +11.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 14.5% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.

Context

  • Operating expenses amounted to 131.9% of revenue in FY2025, down 89.4 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +24.2% holds above the trailing-twelve-month pace of +11.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$28.35M+14.5% QoQ
Last fiscal yearDec 2025
$96.23M+4.7% YoY
LTMMar 2026
$101.75M+11.1% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.2%——
1 year+4.7%——
3-year CAGR-1.4%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
96.23M USD
Year-over-year change
+4.7%
4-year CAGR
-7.6%

Operating Expenses vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +11.1% is the 4th highest of 10, against a peer median of -14.4%.
  • Operating expenses amounts to 149.4% of revenue for CLLS, versus a peer median of 2227.3%.
CLLS Competitors
Operating Expenses for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$172.43M USD+63.7%+67.8%—
DBVTDBV Technologies S.A.LTM Mar 2026$164.05M USD+44.9%+13.2%—
AMRNAmarin Corporation plcLTM Mar 2026$150.13M USD-11.1%-27.1%69.9%
CLLSCellectis S.A.LTM Mar 2026$101.75M USD+11.1%-1.4%149.4%
SLNSilence Therapeutics plcLTM Mar 2026$87.2M USD—+16.9%9463.1%
KRROKorro Bio, Inc.LTM Mar 2026$85.57M USD-14.7%+14.9%2227.3%
ACIUAC Immune S.A.LTM Mar 2026CHF 68.45M CHF-14.4%-1.1%1849.0%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$46.29M USD+25.4%+8.5%—
MREOMereo BioPharma Group plcLTM Mar 2026$37.72M USD-21.8%-10.5%7543.6%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$28.32M USD-53.7%-17.4%—
ANROAlto Neuroscience, Inc.LTM Mar 2026-$55.19M USD-179.1%+31.6%—
Peer median (excluding CLLS) —-14.4%+10.8%2227.3%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.